Qsemble Capital Management LP Purchases Shares of 23,155 Insmed Incorporated (NASDAQ:INSM)

Qsemble Capital Management LP acquired a new position in shares of Insmed Incorporated (NASDAQ:INSM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,155 shares of the biopharmaceutical company’s stock, valued at approximately $1,690,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nisa Investment Advisors LLC grew its holdings in shares of Insmed by 8.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 135 shares in the last quarter. CIBC Asset Management Inc lifted its position in shares of Insmed by 3.5% in the third quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 149 shares in the last quarter. CWM LLC boosted its holdings in Insmed by 11.0% during the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 155 shares during the last quarter. Commerce Bank grew its position in Insmed by 2.4% in the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 163 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on INSM shares. UBS Group increased their price target on Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Truist Financial restated a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a report on Friday, November 1st. Stifel Nicolaus increased their price target on shares of Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Bank of America boosted their price objective on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Finally, TD Cowen raised their target price on shares of Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $83.67.

Insiders Place Their Bets

In other news, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the transaction, the insider now directly owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. This trade represents a 11.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the sale, the insider now owns 100,100 shares in the company, valued at approximately $7,157,150. The trade was a 27.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 78,882 shares of company stock valued at $5,765,446 in the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Insmed Stock Up 1.3 %

NASDAQ INSM opened at $74.09 on Tuesday. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The business has a fifty day moving average price of $72.05 and a two-hundred day moving average price of $66.93. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market capitalization of $13.25 billion, a PE ratio of -13.35 and a beta of 1.12.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. The firm’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.10) earnings per share. Equities analysts expect that Insmed Incorporated will post -5.42 earnings per share for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.